What Is Entrada Therapeutics, Inc. (TRDA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Entrada Therapeutics, Inc.'s intrinsic value is estimated at $7.63, suggesting a +7.3% average upside from the current price of $7.11. While 5 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $28.61 (+302.4%), versus Sentiment SOTP at $0.86 (-87.9%). This +390.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About TRDA?
9 of 13 models are currently active for TRDA. Of these, 5 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates TRDA's intrinsic value at $1.94, implying -72.7% downside from the current price. See which stocks rank higher →
How Does TRDA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, TRDA ranks #121 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Entrada Therapeutics, Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating TRDA should weigh these sector-specific dynamics alongside our model-derived fair values.
Is TRDA a Value Trap?
CirclFi's Value Trap algorithm assigns TRDA a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Entrada Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Entrada Therapeutics, Inc.'s fundamental quality profile registers 6.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +390.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TRDA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TRDA's 9 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad